Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer.

Class IA phosphatidylinositol-3 kinases (PI3Ks) together with AKT and mammalian target of rapamycin (mTOR) comprise the central axis of a complex, interconnected signaling network that integrates signals from growth factors, insulin, nutrients and oxygen to play a critical role in controlling cell growth, proliferation, metabolism, survival, and tumor angiogenesis. De-regulation of these processes is a required hallmark of cancer1 and aberrant activation of the class IA PI3K signaling occurs frequently in many malignancies including non-small cell lung cancer (NSCLC).

[1]  久保 孝文.  MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors , 2010 .

[2]  Nathan T. Ihle,et al.  Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy , 2009, Molecular Cancer Therapeutics.

[3]  P. Jänne,et al.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[5]  A. Hezel,et al.  LKB1; linking cell structure and tumor suppression , 2008, Oncogene.

[6]  H. Sasaki,et al.  Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancer , 2008, Cancer science.

[7]  J. Baselga,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.

[8]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[9]  A. Marchetti,et al.  AKT1E17K in human solid tumours , 2008, Oncogene.

[10]  W. Sellers,et al.  Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.

[11]  L. Zhao,et al.  Class I PI3K in oncogenic cellular transformation , 2008, Oncogene.

[12]  R. Parsons,et al.  The role of PTEN signaling perturbations in cancer and in targeted therapy , 2008, Oncogene.

[13]  Pier Paolo Pandolfi,et al.  The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.

[14]  Lesley Seymour,et al.  Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[16]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[17]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[18]  W. Lam,et al.  PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.

[19]  C. Benes,et al.  Class 1A PI3K regulates vessel integrity during development and tumorigenesis , 2008, Proceedings of the National Academy of Sciences.

[20]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[21]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[22]  M. Meyerson,et al.  Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients , 2008, British Journal of Cancer.

[23]  M. Loda,et al.  Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.

[24]  K. Okkenhaug,et al.  The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ , 2008, Proceedings of the National Academy of Sciences.

[25]  S. Fox,et al.  Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting , 2008, BMC Research Notes.

[26]  F. Natt,et al.  Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. , 2008, Cell metabolism.

[27]  Suzanne F. Jones,et al.  Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Francesca Demichelis,et al.  EML4-ALK fusion lung cancer: a rare acquired event. , 2008, Neoplasia.

[29]  J. Cigudosa,et al.  Expression signatures in lung cancer reveal a profile for EGFR‐mutant tumours and identify selective PIK3CA overexpression by gene amplification , 2008, The Journal of pathology.

[30]  Yuki Togashi,et al.  EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  S. Horvath,et al.  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.

[32]  G. Viglietto,et al.  Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. , 2008, Cell cycle.

[33]  R. Perez-soler,et al.  Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. , 2007, Cancer research.

[34]  Y. Yatabe,et al.  LKB1 gene mutations in Japanese lung cancer patients , 2007, Cancer science.

[35]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[36]  H. Sasaki,et al.  PIK3CA gene amplification in Japanese non-small cell lung cancer. , 2007, Lung cancer.

[37]  H. Sugimura,et al.  PIK3CA mutation and amplification in human lung cancer , 2007, Pathology international.

[38]  J. Minna,et al.  Prevalence and specificity of LKB1 genetic alterations in lung cancers , 2007, Oncogene.

[39]  D. Neil Hayes,et al.  LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.

[40]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[41]  D. Alessi,et al.  Identification of Protor as a novel Rictor-binding component of mTOR complex-2. , 2007, The Biochemical journal.

[42]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[43]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[44]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[45]  Hong Wu,et al.  Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. , 2007, Cancer cell.

[46]  S. Cook.  Faculty Opinions recommendation of Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. , 2007 .

[47]  P. Jänne,et al.  Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  G. Stamp,et al.  Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.

[49]  M. Zvelebil,et al.  Exploring the specificity of the PI3K family inhibitor LY294002. , 2007, The Biochemical journal.

[50]  G. Thomas,et al.  hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling. , 2007, Current Opinion in Cell Biology.

[51]  Timothy J. Griffin,et al.  Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 , 2007, Nature Cell Biology.

[52]  H. Sasaki,et al.  PIK3CA mutation status in Japanese lung cancer patients. , 2006, Lung cancer.

[53]  P. Houghton,et al.  mTOR and cancer therapy , 2006, Oncogene.

[54]  Shi-Yong Sun,et al.  LKB1 mutation in large cell carcinoma of the lung. , 2006, Lung cancer.

[55]  Y. Yatabe,et al.  PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[56]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[57]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[58]  K. Okkenhaug,et al.  Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation , 2006, Nature.

[59]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[60]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[61]  Targeting mTOR signaling for lung cancer therapy. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[62]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[63]  P. Vogt,et al.  Cancer-specific mutations in PIK3CA are oncogenic in vivo , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[64]  W. Travis,et al.  Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Somasekar Seshagiri,et al.  Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.

[66]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[67]  M. Loda,et al.  The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .

[68]  J. Engelman,et al.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.

[69]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  K. Aldape,et al.  PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. , 2005, Human pathology.

[71]  C. Johannessen,et al.  Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1 , 2005, Molecular and Cellular Biology.

[72]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[73]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[74]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[75]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[76]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[77]  M. Loda,et al.  The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Testa,et al.  Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. , 2004, Carcinogenesis.

[79]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[80]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[81]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[82]  J. Carretero,et al.  Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene , 2004, Oncogene.

[83]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[84]  R. Pearson,et al.  mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBF† , 2003, Molecular and Cellular Biology.

[85]  David Sidransky,et al.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. , 2002, Cancer research.

[86]  Li Mao,et al.  Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  I. Campbell,et al.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.

[88]  I. Gaidarov,et al.  The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. , 2001, Molecular cell.

[89]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[90]  S. Jackson,et al.  Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. , 1999, Cancer research.

[91]  R. Brezinschek,et al.  Mutation analysis of the PTEN/MMAC1 gene in lung cancer , 1998, Oncogene.

[92]  David I. Smith,et al.  PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers , 1998, Oncogene.

[93]  Frank McCormick,et al.  Akt activation by growth factors is a multiple-step process: the role of the PH domain , 1998, Oncogene.

[94]  J. Yokota,et al.  Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers , 1998, Genes, chromosomes & cancer.

[95]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.